NASDAQ:CNTB Connect Biopharma Q2 2026 Earnings Report $1.93 -0.83 (-30.07%) As of 09/3/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Connect Biopharma EPS ResultsActual EPS-$0.27Consensus EPS -$0.31Beat/MissBeat by +$0.04One Year Ago EPSN/AConnect Biopharma Revenue ResultsActual Revenue$2.75 millionExpected Revenue$0.74 millionBeat/MissBeat by +$2.01 millionYoY Revenue GrowthN/AConnect Biopharma Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time4:00PM ETUpcoming EarningsConnect Biopharma's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Quarterly report(10-Q) Connect Biopharma Earnings HeadlinesConnect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 3 at 4:05 PM | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB) and Stryker (SYK)August 28, 2026 | theglobeandmail.comBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9.1 billion dollars, according to CNBC. Before any Anthropic IPO arrives, one publicly accessible vehicle already lists Anthropic as its largest holding, available through a regular brokerage with no accredited-investor requirement. History showed how fast access tightened once SpaceX became a headline name. Alexander Green of The Oxford Club says this window is open now. | The Oxford Club (Ad)Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 12, 2026 | finance.yahoo.comConnect Biopharma: Attempting To Differentiate Rademikibart From DupixentJuly 23, 2026 | seekingalpha.comConnect Biopharma Holdings (CNTB) Receives a New Rating from OppenheimerJuly 10, 2026 | theglobeandmail.comSee More Connect Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Connect Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Connect Biopharma and other key companies, straight to your email. Email Address About Connect BiopharmaConnect Biopharma (NASDAQ:CNTB) Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases. The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis. A second clinical-stage program, CBP-701, selectively inhibits signaling through tumor necrosis factor receptor 1 (TNFR1), a strategy designed to preserve beneficial TNFR2 activity while reducing the risk of systemic immunosuppression. Together, these candidates reflect Connect Biopharma’s commitment to developing differentiated therapies with potentially improved safety and efficacy profiles. Since its founding in 2015, Connect Biopharma has advanced its pipeline through early-phase clinical trials and established strategic partnerships to support long-term development goals. The company completed its initial public offering on the Nasdaq Global Market under the ticker CNTB in 2021, raising capital to fund ongoing studies and expand its research capabilities. Its clinical programs are being evaluated across multiple geographies, including North America and the Asia-Pacific region. Connect Biopharma is led by an executive team and board of directors with extensive experience in biotechnology, pharmaceutical development and commercialization. Leveraging a blend of scientific rigor and clinical expertise, the management group aims to bring novel immunology treatments to patients with high unmet medical need.View Connect Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
